- Home >
- Life Sciences >
- Pharmaceutical >
US Drug Delivery Systems Market
US Drug Delivery Systems Market
- Report price : $ 4 500
- Publication date : March 2008
- Length : 250 pages
US Drug Delivery Systems Market
Demand to grow more than 10% annually through 2012
US demand for drug delivery systems is projected to expand more than ten percent annually to $132 billion in 2012. Growth opportunities for drug delivery systems extend into all therapeutic classes of pharmaceuticals and encompass a wide range of compounds and formulations. Central nervous system, respiratory and hormone and related agents will remain the top three applications based on the special formulating needs of medicines for conditions such as arthritis, multiple sclerosis, asthma, allergies and cancer. However, favorable growth opportunities will emerge for drug delivery systems in most other therapeutic classes due to safety and efficacy shortcomings in many conventional medicines.
Parenteral types to exhibit best growth opportunities
Oral drug delivery systems will remain the largest method used for drug delivery. Orally disintegrating tablets and transmucosal drugs will generate strong growth opportunities in the delivery of pain control and other critical care medication. Ease of administration advantages will promote the widening use of chewable tablet dosages for nutritional, respiratory and central nervous system agents, especially pediatric preparations. Better solubility and pharmacokinetic actions will lead to rapid growth both in the number and sales of oral nanoparticle drugs. Among pharmaceutical dosage formulations, parenteral preparations will provide the strongest growth opportunities for drug delivery systems. Precise targeting advantages in the treatment of cancer and other debilitating diseases will broaden demand for therapeutic monoclonal antibodies. Extended circulation and reduced toxicity benefits will expand the range of indications served by polymer- and liposome-encapsulated drugs, especially in the areas of cancer, neurological and anti-infective therapies. Ease of administration and infection prevention advantages will boost the market for parenteral drugs and solutions sold in prefilled syringes and premixed IV systems. An increasing incidence of chronic respiratory conditions, coupled with the need for safer and more effective therapies, will boost growth prospects for inhalation drug delivery systems. Based on widespread use in asthma therapy, dry powder inhaler formulations will continue to record the largest share of sales. However, metered dose drugs will see slightly faster gains in demand due to ongoing improvements in particle size and propellent safety. Lastly, transdermal patches will continue to broaden pharmaceutical applications as advances in administration modalities and design lead to new uses in pain control and cardiovascular medication.
Study coverage
It presents historical demand data (1997, 2002, 2007) plus forecasts for 2012 and 2017 by type and application. The study also considers US market environment factors, evaluates company market share and profiles 43 industry competitors.
RELATED REPORTS
Parkinson’s Disease Market analysis and forecasts, 2008-2012, 2017 and 2022
- $ 2 501
- March 2008
- 150 pages
Parkinson's disease (PD) is the second most common neurological disorder, affecting approximately 4.1m people worldwide. As the prevalence rate of PD is set to rise significantly in the coming years, clinical interventions will play a major role in combating the wide spectrum of unmet needs associat ...
Industries : Pharmaceutical, Therapy | Countries : USA, Japan, Germany, Spain, France, Italy, United Kingdom
Innovations in Bioinformatics: Emerging tools for drug discovery and development
- $ 3 835
- January 2008
- 253 pages
R&D laboratories are co-ordinating the analysis of increasing volumes of disparate biological data, largely comprised of gene and protein sequences. Bioinformatics-enabled data management has enabled companies to improve productivity within their R&D programmes by identifying new drug targets, diagn ...
Industries : Pharmaceutical | Countries : USA
The Global Pain Pharmaceutical Market Analysis & Forecasts 2007-2022
- $ 3 621
- September 2007
- 200 pages
The global pain pharmaceutical market is set to become a serious growth area experiencing a compound annual growth rate of 4.56% to 2012.Visiongain's latest report, ``The Global Pain Pharmaceutical Market 2007-2022 ``, explains just how this market will experience growth over the medium term future. ...
Industries : Pharmaceutical | Countries : Canada, USA
The Anti-Migraine Market 2007-2022
- $ 3 621
- November 2007
- 200 pages
Migraine is a serious neurological disorder characterised by recurrent headaches, varying in severity and frequency. Accounting for the loss of over 100 million working days in the US alone, the economic cost and social impact of migraine is significant. Furthermore, the people most susceptible to m ...
Industries : Pharmaceutical, Skin Care Products | Countries : USA, France
The World Dermatological Market Analysis & Forecasts 2007-2022
- $ 3 621
- November 2007
- 200 pages
Most skin disorders are not fatal but most people are affected globally. The revenue of dermatological market in 2006 was $16bn, which is a 5.1% when compared with 2003. The common skin disorders include acne, dermatitis, psoriasis, rosacea, urticaria and hair loss. Due to the aesthetic awareness in ...
Industries : Pharmaceutical, Skin Care Products | Countries : USA, United Kingdom
Alexion Pharmaceuticals Inc: Premium Company Profile
- $ 495
- February 2008
- 52 pages
IntroductionAlexion Pharmaceuticals (Alexion) is a biotechnology company engaged in the discovery and development of therapeutic products for the treatment of hematological diseases, cancer, and autoimmune disorders. The company started marketing Soliris in the US in March 2007 for the treatment of ...
Industries : Pharmaceutical | Countries : USA
Iasis Healthcare LLC - SWOT Analysis
- $ 125
- March 2008
- 24 pages
Datamonitor's Iasis Healthcare LLC - SWOT Analysis Company Profile is the essential source for top-level company data and information. The report examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy. ...
Industries : Pharmaceutical | Countries : USA
Abbott Laboratories - SWOT Analysis
- $ 125
- March 2008
- 45 pages
Datamonitor's Abbott Laboratories - SWOT Analysis Company Profile is the essential source for top-level company data and information. The report examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy. ...
Industries : Pharmaceutical | Countries : USA
Progenics Pharmaceuticals Inc - SWOT Analysis
- $ 125
- March 2008
- 31 pages
Datamonitor's Progenics Pharmaceuticals Inc - SWOT Analysis Company Profile is the essential source for top-level company data and information. The report examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and ...
Industries : Pharmaceutical | Countries : USA
Pfizer Inc - SWOT Analysis
- $ 125
- March 2008
- 46 pages
Datamonitor's Pfizer Inc - SWOT Analysis Company Profile is the essential source for top-level company data and information. The report examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy. Pfizer, o ...
Industries : Pharmaceutical | Countries : USA
Related industries
reportlinker.com © Copyright 2009. All rights reserved